HRD — Targeted Therapies, Trials & Pipeline

A broader genomic-scar phenotype beyond BRCA that predicts PARP-inhibitor benefit, especially in ovarian cancer.

Approved drugs targeting HRD

Investigational pipeline agents

Landmark trials